ERAS logo

Erasca Inc. (ERAS)

$13.89

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ERAS

Market cap

$4.87B

EPS

-0.99

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.693259

Price on ERAS

Previous close

$15.11

Today's open

$15.51

Day's range

$13.60 - $15.69

52 week range

$2.52 - $24.28

Profile about ERAS

CEO

Jonathan E. Lim

Employees

103

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

350956416

Issue type

Common Stock

ERAS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ERAS

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat

ERAS-0015 will be evaluated with PRMT5 inhibitor navlimetostat in MTAP-deleted pancreatic cancer in Phase 1/2 trial

news source

GlobeNewsWire • a day ago

news preview

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise

SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it will host a virtual investor event on Friday, November 20, 2026, at 8:00 a.m. Eastern Time to discuss updated Phase 1 data for ERAS-0015, a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors, and other updates.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Erasca Reports Third Quarter 2026 Business Updates and Financial Results

ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS-0015 monotherapy and nonclinical ERAS-0015/ERAS-4001 combination data to be presented at ENA; expect preliminary ERAS-4001 data in H2 2026 and ERAS-0015 data in H1 2027 Cash, cash equivalents, and marketable securities of $948 million as of September 30, 2026 SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended September 30, 2026. “The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens,” said Jonathan E.

news source

GlobeNewsWire • Nov 12, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

PRNewsWire • Nov 12, 2026

news preview

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer and Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Phase 1/2 study of oral PRMT5 inhibitor vopimetostat in combination with pan-RAS molecular glue ERAS-0015 in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC) and MTAP-deleted/RAS-mutant non-small cell lung cancer (NSCLC) is now open for enrollment. “The encouraging clinical activity, durability and tolerability observed to date with vopimetostat in combination with RAS inhibition reinforce our belief that co-targeting PRMT5 and RAS represents a promising new frontier in the treatment of pancreatic cancer and potentially other RAS-driven cancers,” said Malte Peters, M.D.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Erasca to Present at Upcoming Conferences in November

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2026 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim 3 rd Annual Healthcare Innovation Conference Location: InterContinental Boston, Boston, MAFormat: Fireside Chat Date and Time: Tuesday, November 10, 3:30 pm Eastern Time Stifel 2026 Healthcare Conference Location: Lotte New York Palace, New York, NY Format: Fireside Chat Date and Time: Wednesday, November 11, 9:20 am Eastern Time Jefferies Global Healthcare Conference Location: The Waldorf Hilton, London, UK Format: Fireside Chat Date and Time: Wednesday, November 18, 12:30 pm Greenwich Mean Time A live audio webcast of the events will be available online at Erasca.com/events.

news source

GlobeNewsWire • Nov 3, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Erasca, Inc. - ERAS

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

news source

GlobeNewsWire • Oct 27, 2026

news preview

ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $ERAS--ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law.

news source

Business Wire • Oct 23, 2026

news preview

Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower

Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling trials ahead. Daraxonrasib's FDA approval validates the RAS mechanism, shifting competition to tolerability and dose intensity, where ERAS-0015 shows potential differentiation. ERAS-0015 demonstrates strong tolerability, no dose-limiting toxicities, and high dose intensity, supporting its case for durable efficacy in key indications.

news source

Seeking Alpha • Oct 5, 2026

news preview

ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS).

news source

GlobeNewsWire • Sep 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Erasca Inc.

Open an M1 investment account to buy and sell Erasca Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ERAS on M1